SCHEMBL4527276

SCHEMBL4527276

CC(N)c1ccc(C(=O)Nc2ccncc2)cc1NCc1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.51
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ROCK1 Q13464 2/20 0.48
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
MAPT P10636 5/20 0.45
ALDH1A1 P00352 5/20 0.45
RAB9A P51151 3/20 0.45
USP2 O75604 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM4E B2RXH2 4/20 0.44
KDM6B O15054 1/20 0.44
KDM4A O75164 1/20 0.44
KDM5C P41229 1/20 0.44
KDM4D Q6B0I6 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
HTT P42858 1/20 0.42
POLB P06746 2/20 0.42
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4513943 0.99 ROCK2 (0.50) ROCK2LMNASMN1; SMN2ROCK1MEN1
SCHEMBL4527616 0.84 ROCK2 (0.54) ROCK2LMNASMN1; SMN2ROCK1RAB9A
SCHEMBL14547284 0.84 ROCK2 (0.54) ROCK2LMNASMN1; SMN2ROCK1RAB9A
SCHEMBL13713261 0.83 SMN1; SMN2 (0.57) ROCK2LMNASMN1; SMN2ROCK1MEN1
Hydrochloric Acid SCHEMBL4519823 0.83 ROCK2 (0.53) ROCK2LMNASMN1; SMN2ROCK1RAB9A
SCHEMBL4520669 0.79 ROCK2 (0.64) ROCK2LMNAROCK1MEN1KMT2A
SCHEMBL4517023 0.78 ROCK2 (0.61) ROCK2LMNASMN1; SMN2ROCK1MEN1
Hydrochloric Acid SCHEMBL4511190 0.77 ROCK2 (0.62) ROCK2LMNASMN1; SMN2ROCK1MEN1
SCHEMBL4519239 0.76 ROCK2 (0.57) ROCK2SMN1; SMN2ROCK1MEN1KMT2A
Hydrochloric Acid SCHEMBL4515980 0.75 ROCK2 (0.56) ROCK2SMN1; SMN2ROCK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US claimed
CN-101287707-A Kinase inhibitors DEVGEN NV (BE) 2008-10-15 CN claimed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 EP claimed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO claimed
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
US-20090233960-A1 Kinase Inhibitors DEVGEN NV (BE) 2009-09-17 US disclosed
CN-101287707-A Kinase inhibitors DEVGEN NV (BE) 2008-10-15 CN disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233960-A1 Kinase Inhibitors ROCK1, MAP3K1, MAP3K11 ROCK2 32/4885LMNA 878/4885SMN1; SMN2 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.